TB and HIV, and other comorbidities
People living with HIV are 15-22 times more likely to develop TB than persons without. TB is the most common presenting illness among people living with HIV, including among those taking antiretroviral treatment, and it is the major cause of HIV-related deaths. Sub-Saharan Africa bears the brunt of the dual epidemic, accounting for approximately 84% of all deaths from HIV-associated TB in 2018. To address HIV-related TB WHO recommends a 12 point package of collaborative TB/HIV activities. These aim to create collaboration between TB and HIV programmes, reduce the burden of TB among people living with HIV and the burden of HIV among TB patients.
7.3 millionthrough scale-up of collaborative TB/HIV activities since 2005Read 10 facts on TB-HIV
HIV-positive TB cases
862 000people living with HIV estimated to have fallen ill with TB in 2018.Read the Global Tuberculosis Report
251 000people living with HIV estimated to have died from TB, a preventable and curable disease.Read the 2019 TB/HIV fact sheet
News, events and meetings
Synergising Action to Address the Burden of Tuberculosis and NCDs in Vulnerable Populations
A panel discussion entitled Synergising Action to Address the Burden of Tuberculosis and NCDs in Vulnerable Populations was organized by the Global TB Programme at the WHO Global Meeting to Accelerate Progress on SDG target 3.4 on NCDs and Mental Health in Oman, 9-12 October. During the session representatives from Mexico, Oman, the Russian Federation and the United Republic of Tanzania described their experiences, challenges and enablers for ensuring integrated care for TB, NCDs and mental health. For more information please visit the link below.
WHO and Treatment Action Group convened a satellite event at the 10th International AIDS Society Conference (IAS 2019) entitled Urine LAM tests: A golden opportunity to end TB deaths among people with advanced HIV, in Mexico on 22nd July 2019. The session shared the latest evidence on diagnostic tests, provided a broad overview of the update to the WHO guidelines for the use of the lateral flow urine lipoarabinomannan (LF-LAM) assay, reviewed the reasons behind poor policy uptake by countries and shared best practice and advocacy efforts by civil society to promote urine LF-LAM uptake. For more information please see the links below.
CROI 2019-Affiliated HIV/TB Research Frontiers Meeting
WHO convened a meeting in conjunction with CROI 2019, entitled "New approaches to TB prevention in people living with HIV: From long-acting injectables to the perfect vaccine" on Monday 4th March 2019 in Seattle, USA. The meeting was chaired by Richard Chaisson of Johns Hopkins Medicine and Diane Havlir of the University of California, San Francisco. Participants reviewed the longer-term prospects for TB prevention among people living with HIV and discussed opportunities, challenges and research implications for developing a durable and acceptable method of TB prevention. For more details including the report with links to the presentations, please visit the links below.
TB/HIV Side Event at the UN General Assembly High-Level Meeting on Ending TB
On the morning of the historic UN General Assembly High-Level Meeting on Ending TB on 26 September 2018, WHO in collaboration with partners, convened a breakfast event to catalyze the scale-up of integrated, community-based care for TB and HIV to reach the SDG targets of ending TB and AIDS by 2030. For more details on the event and on outcomes from the UN High-Level meeting relevant to the response to HIV-associated TB, please visit the links below:
TB at the 22nd International AIDS Society Conference, 2018
In collaboration with CDC, WHO convened a consultation "TB preventive preventive treatment among people living with HIV: Time for Action!" on 24th July 2018 in conjunction with AIDS 2018. The consultation reviewed global progress in implementation and scale-up of TB preventive treatment efforts, shared country experiences, identified key barriers and discussed opportunities to support increased implementation and scale-up. For more information on the consultation and for the roadmap of sessions focusing on HIV-associated TB with links to presentations and videos, please visit the links below:
CROI 2018-Affiliated HIV/TB Research Frontiers Meeting
WHO organised an HIV/TB Research Frontiers meeting entitled "Short-Course Rifamycin Regimens and Dolutegravir: Silver Bullets?", in conjunction with the Conference on Retroviruses and Opportunistic Infections (CROI 2018) on March 4, 2018. The meeting was chaired by Richard Chaisson of Johns Hopkins Medicine, and Constance Benson of the University of California, San Diego. The main aim of the meeting was to stimulate high level scientific debate around the opportunities, challenges, and scientific research implications posed by the latest short-course rifamycin-based TB preventive regimens in the context of the latest generation of antiretroviral drugs such as Dolutegravir. For more details on this meeting and on coverage of HIV-associated TB at the conference itself, please visit the links below.
IAS 2017 and Consultation on WHO Ministerial Conference on ending TB in a Sustainable Development Era
In preparation for the first WHO Ministerial Conference on Ending TB in the Sustainable Development Era to be held in Moscow in November 2017, WHO convened a consultation on 25th July 2017 at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris, France, on actions needed to galvanize political momentum and eliminate TB deaths among people living with HIV. Click on the links below for further details on the meeting and on TB at IAS 2017.
Regional consultation meeting to support country implementation of the top 10 indicators to monitor the End TB Strategy, programmatic management of latent TB infection and collaborative TB/HIV activities
The WHO Global TB Programme and the department of HIV/AIDS and Global Hepatitis programme and the Global Fund Secretariat jointly organized a consultative meeting to support country implementation of the top 10 indicators to monitor the End TB Strategy, collaborative TB/HIV activities and programmatic management of latent TB infection, on 20-22 September 2016 at Nairobi, Kenya.
TB 2016 Conference
In recognition of the need for greater attention to TB, the International AIDS Society hosted TB2016 – a two-day global conference dedicated to TB, immediately prior to AIDS 2016 in Durban, South Africa. The conference brought together scientists, researchers, policy makers and advocates, to galvanize political leadership and commitment to end TB by 2030, as set out in the UN Sustainable Development Goals.
AIDS 2016 Conference
The International AIDS Society conference, AIDS 2016, held in Durban, South Africa from 18 to 22 July was attended by more than 18,000 delegates to discuss the global HIV response. In addition to the pre-conference, dedicated to TB, the main HIV conference included numerous sessions on HIV-associated TB, including a WHO-organized workshop to expedite the diagnosis and treatment of HIV-associated TB among people living with HIV.
UN General Assembly 2016
A WHO-organized Ministerial Panel discussion was convened prior to the opening plenary of the UN High-Level Meeting on ending AIDS on 8 June 2016. The panel discussion was convened by the UN Special Envoy on TB, Eric Goosby and opened by WHO’s Assistant Director General on HIV, TB, Malaria and Neglected Tropical Diseases, Ren Minghui, and Chair of the Board of the Stop TB Partnership and Minister of Health of South Africa, Aaron Motsoaledi.
TB, HIV and Malaria at the Women Deliver conference
A symposium on the “Female Face of Communicable Diseases” was organized by WHO in collaboration with partners, at the Women Deliver Global Conference in Copenhagen, Denmark on 18th May 2016. The session aimed to raise the importance of TB, and other communicable diseases in women’s health and discussed the need for a holistic and integrated healthcare delivery model, from policy to care recipient level.
Consolidated guidelines for people who inject drugs
People who inject drugs (PWID) are at increased risk of TB, irrespective of HIV status, and TB is a leading cause of HIV-related mortality among PWID. PWID are also disproportionately affected by HIV, hepatitis B and hepatitis C. These guidelines, released in March 2016, consolidate the latest WHO recommendations relating to the management of TB, HIV-associated TB, HIV, viral hepatitis B and C, drug dependence, as well as of alcohol dependence, malnutrition, mental illness and psycho-social needs.
- Latent TB Infection: Updated and consolidated guidelines for programmatic management
- WHO policy on collaborative TB/HIV activities
- Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Second Edition 2016
- Consolidated guidelines for people who inject drugs
Algorithms for diagnosing and managing HIV-associated TB
- Policy and checklist for TB Infection Control
- Guide to monitoring and evaluation for collaborative TB/HIV activities - 2015 revision
Slide show on 2019 Global TB Report update on HIV-associated TB